Aug 5 2010
TapImmune Inc. (OTCBB:TPIV) announced that it has signed a Research and Technology License Option Agreement with Mayo Clinic, Rochester, MN, for the development of a smallpox vaccine technology. Research will be conducted by Gregory Poland M.D., at Mayo Clinic, to evaluate novel peptide antigens together with TapImmune's proprietary TAP technology. TapImmune also has an exclusive Option to the smallpox vaccine technology after research studies have been completed under the terms of the agreement.
TapImmune Inc. is developing vaccines for the treatment of cancer and infectious disease using its proprietary TAP technology platform. In preclinical studies this technology improved the efficacy of a vaccinia virus vaccine by over a 100 fold.
Dr Glynn Wilson, Chairman & CEO of TapImmune, stated, "The opportunity to license this technology builds on our experience of enhancing the potency of a smallpox vaccine. We believe that this technology gives TapImmune the potential to develop a new generation of safe and cost effective smallpox vaccines that will have widespread use."
Personalized anti-tumor vaccine enhances immunotherapy for liver cancer